Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity

被引:138
作者
Lashkari, K
Hirose, T
Yazdany, J
McMeel, JW
Kazlauskas, A
Rahimi, N
机构
[1] Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02114 USA
[2] Schepens Retina Associates, Boston, MA USA
[3] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[4] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA
关键词
D O I
10.1016/S0002-9440(10)65004-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Although the roles of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in angiogenesis are well described, the putative roles of these factors in retinopathy of prematurity (ROP) remain unknown We evaluated VEGF and HGF protein levels in subretinal fluid of eyes with ROP, and expression of their corresponding receptors in retrolental membranes associated with stage 5 ROP, We examined subretinal fluid samples from eyes using rhegmatogenous retinal detachment as a control. VEGF and HGF were differentially elevated in eyes with ROP, In Stage 5 ROP (n = 22), the mean VEGF and HGF levels were 14.77 +/- 14.01 ng/ml and 16.56 +/- 9.62 ng/ml, respectively. Interestingly, in patients with active stage 4 ROP, mean VEGF levels were highly elevated (44.16 +/- 18.72 ng/ml), whereas mean HGF levels remained very low (4.77 +/- 2.50 ng/ml). Next, we investigated is vivo expression of VEGF receptor-2 and HGF receptor in retrolental membranes from 16 patients with stage 5 ROP. Both VEGF receptor-2 and HGF receptor proteins were detected mainly in posterior portions of the membrane as well as in vessel walls and along the retinal interface where angiogenesis was active. These findings together suggest that VEGF and HGF play important roles in the pathogenesis of ROP.
引用
收藏
页码:1337 / 1344
页数:8
相关论文
共 46 条
[1]   HYPOXIC REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR IN RETINAL CELLS [J].
AIELLO, LP ;
NORTHRUP, JM ;
KEYT, BA ;
TAKAGI, H ;
IWAMOTO, MA .
ARCHIVES OF OPHTHALMOLOGY, 1995, 113 (12) :1538-1544
[2]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[3]   VASCULAR ENDOTHELIAL GROWTH-FACTOR ACTS AS A SURVIVAL FACTOR FOR NEWLY FORMED RETINAL-VESSELS AND HAS IMPLICATIONS FOR RETINOPATHY OF PREMATURITY [J].
ALON, T ;
HEMO, I ;
ITIN, A ;
PEER, J ;
STONE, J ;
KESHET, E .
NATURE MEDICINE, 1995, 1 (10) :1024-1028
[4]  
Behzadian MA, 1998, GLIA, V24, P216, DOI 10.1002/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.3.CO
[5]  
2-D
[6]  
BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11
[7]   FACTORS CONTROLLING GROWTH, MOTILITY, AND MORPHOGENESIS OF NORMAL AND MALIGNANT EPITHELIAL-CELLS [J].
BIRCHMEIER, C ;
MEYER, D ;
RIETHMACHER, D .
INTERNATIONAL REVIEW OF CYTOLOGY - A SURVEY OF CELL BIOLOGY, VOL 160, 1995, 160 :221-266
[8]  
BREIER G, 1992, DEVELOPMENT, V114, P521
[9]  
CHAN AML, 1987, ONCOGENE, V1, P229
[10]  
COGAN DG, 1986, ARCH OPHTHALMOL-CHIC, V104, P747